ArticleAntimicrobial agents and chemotherapy2017
Rifabutin Is Active against Mycobacterium abscessus Complex.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 138 citations in OpenAlex.
- Protective mechanism of action of the antifungal drug naftifine againstAntimicrobial agents and chemotherapy · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Defining the mechanism of action of the nitrofuranyl piperazine HC2210 against Mycobacterium abscessus.npj antimicrobials and resistance · 2025Article
- In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- Next-generation rifamycins for the treatment of mycobacterial infections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis andEuropean clinical respiratory journal · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Review
- Management ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Broad-Spectrum In Vitro Activity ofAntibiotics (Basel, Switzerland) · 2024Article
- TargetingRSC medicinal chemistry · 2023Review
- Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.Microbiology spectrum · 2023Article
- ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerantAntimicrobial agents and chemotherapy · 2023Article
- Characterization ofAntimicrobial agents and chemotherapy · 2023Article
- Conjugation of Vancomycin with a Single Arginine Improves Efficacy against Mycobacteria by More Effective Peptidoglycan Targeting.Journal of medicinal chemistry · 2023Article
- Article
- CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.Microbiology spectrum · 2023Article
- Article
- Rifaximin potentiates clarithromycin againstJAC-antimicrobial resistance · 2023Article
- A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.Antimicrobial agents and chemotherapy · 2023Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.